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PATTERNS OF PATIENT WITHDRAWAL FROM BCG TREATMENT FOR 
BLADDER CANCER: A RETROSPECTIVE TIME INTERVAL ANALYSIS
ABSTRACT 
Research Aims
What were the patterns that have been recorded for withdrawal from treatment? 
What individual factors influenced withdrawal from BCG treatment? 
Literature Review
Bacillus Calmette-Guerin (BCG) vaccine was first introduced at the turn of the 19-20th 
century and since the 1970s has become significant in the treatment of non-muscle 
invasive bladder cancer (NMIBC). It is concerning to note that little is known about the 
patient experience of this intravesical treatment, which is particularly concerning. 
Despite over 50 years of clinical use, early withdrawal from treatment rates of between 
32% - 86% have been reported in the literature. This study sought to estimate the rate 
of non-completion of BCG regime in one English National Health Service Cancer Unit 
and identify factors that contributed to patients’ decisions to withdraw.
Methodology
A retrospective observational time interval study of a consecutive sample 234 case 
records of patients who underwent intravesical BCG treatment in one English National 
Health Service Cancer Unit, using time to event analysis. The population for this 
review was from a large metropolitan area in England, including a large northern town 
and satellites where heavy industry had dominated. 
Results
The overall withdrawal rate was 211 (90%) prior to completion of induction and 
maintenance regime. The majority, 107 (46%) withdrew from treatment within the first 
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year. Age, number of side effects and symptoms, and contact with CNS were all 
associated with withdrawal.
Conclusions
The data has shown that age, side effects, contact details and information giving may 
be factors that contribute to a patient deciding whether they stay on treatment or 
withdraw from it.
Funding / Competing interests 
None to declare
Keywords 
Bladder cancer, Non-muscle invasive bladder cancer, Urothelial cancer, Bacillus 
Calmette-Guerin, BCG, Intravesical treatment, Early withdrawal
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In 2015, there were over 10,000 new cases of bladder cancer recorded in the UK only 
1. This accounts for 3% of all new cancer cases, with males being three times more 
likely to develop the disease than females. It is highest in people aged 85-89 years. 
The incidence rates for bladder cancer have been seen to be falling since the early 
1990’s. Reasons offered for this decline include reductions in tobacco smoking or 
exposure to occupational carcinogens, particularly amongst men 2. There has also 
been a shift from industrial to predominantly service occupations in the UK 3. Although 
tobacco smoking is still associated with around 50% of bladder cancers 4–7 and more 
prevalent amongst people living in deprived areas 1.
Transitional cell bladder cancer or urothelial cancer accounts for approximately 90% 
of all bladder cancers in the UK 1. Non-muscle invasive, superficial or early, bladder 
cancer is characterised by abnormal cells localised to the lining of the bladder. Apart 
from recommended lifestyle changes such as smoking cessation, following a 
transurethral resection of bladder tumour (TURBT) intravesical treatment with Bacillus 
Calmette-Guerin (BCG) is considered the gold standard for preventing recurrence and 
disease progression in non-muscle invasive bladder cancer (NMIBC)  8. Intravesical 
treatment involves instilling BCG into the bladder via a catheter. A proportion of 
patients, in some studies as high as 86%, fail to complete treatment 9. This low level 
of concordance could have consequences in terms of disease progression and 
ultimately need for radical surgical interventions.
At the turn of the 19 - 20th century Albert Calmette and Camille Guerin isolated an 
attenuated live strain of Mycobacterium bovis bacillus, a live vaccine against 
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tuberculosis, known as BCG 10,11. During a series of post mortems in 1929, Pearl noted 
a lower incidence of bladder cancer in patients with tuberculosis 12. Subsequent 
laboratory studies demonstrated the anti-tumour effects of BCG against several 
malignant cell lines 13–16. In the late seventies Morales et al. (1976) undertook a 
preliminary study evaluating the effects of BCG treatment on nine patients with 
NMIBC. Study participants were treated with intravesical BCG once a week for six-
weeks, achieving a complete response rate in 7 (78%) of patients 17. The effectiveness 
of this regime was later replicated in both the American South Western Oncology 
Group (SWOG) and the Memorial Sloan-Kettering Hospital in larger well designed 
control trials 18–21.
Several well designed randomised clinical trials have since compared TURBT as a 
single treatment, against a TURBT followed by BCG 18,22–24. Other randomised trials 
and meta-analyses compared various combinations of TURBT, chemotherapy and 
BCG regimes 9,25–30. These studies demonstrated significant reductions in NMIBC 
recurrence rates of up to 57% in patients treated with BCG, compared to rates of up 
to 32% when treated with TURBT alone, or with chemotherapy. 
Globally sub strains of BCG such as Pasteur, TICE, Armand-Frappier, Glaxo, 
Connaught and others are in use 31 creating an absence of clarity regarding optimum 
strain or dose, as well as different regimes and doses 30–32. A consensus statement 
concluded that regimens other than SWOG have not shown the same reliability 33. 
Only one study compared two strains head to head 34. They compared the Connaught 
and TICE strains and showed a statistically significant difference (p<0.002) in five-year 
recurrence-free survival for Connaught (75%) over TICE (46%) treated patients.
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At present there remains no overwhelming evidence indicating the optimal efficacy for 
the most appropriate induction and maintenance regime. This is illustrated in table 1. 
Induction BCG was first introduced by Morales et al. and is normally given using a six-
weekly regime. Results from the SWOG 8507 trial9 and European Organisation for 
Research and Treatment of Cancer (EORTC) 30911 trial 27, recommend an induction 
regimen of weekly instillations for six weeks, followed by a maintenance schedule of 
weekly instillations for three weeks at months 3, 6, 12, 18, 24, 30, and 36 for a total of 
27 instillations for three years. Maintenance for three years was affirmed by a 
subsequent EORTC trial 35. This regimen has now been recommended by the 
American Urological Association (AUA) and the European Association of Urology 
(EAU) as well as in local guidelines 36–39. The EAU guidance recommends that at least 
one year of maintenance treatment is required to gain superior outcomes over 
Mitomycin (MMC) treatment 8. The absence of an established optimal induction and 
maintenance schedule may be as a consequence of the wide variations in regimes in 
current use 40–42. Moreover, the original and subsequent trial design irrespective of 
minor variations have all adopted an induction and maintenance model yet report high 
levels of attrition. Clinical practice has adopted the same model.
This paper presents the results of a study investigating the clinical experiences of 
patients receiving BCG treatment, using retrospective time interval analysis from case 
notes. This was the first phase in a larger mixed methods study exploring the reasons 
why patients withdrew from BCG treatment early.
Insert Table 1 
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From the literature the following question emerged which the time interval analysis 
sought to answer: what were the patterns that have been recorded for withdrawal from 
treatment? and what individual factors influenced withdrawal from BCG treatment? 
2. Methods 
A retrospective time interval analysis was undertaken. 
3.1. Population 
The study was undertaken in a cancer centre based in a large National Health Service 
Hospital Trust serving a large metropolitan area in Northern England. The area had 
traditionally been characterised by heavy industries such as coal mining and textiles, 
but, latterly as chemical manufacturing. One in six of the local population are aged 65 
years or over 43.
This population is diverse and undergoing change. Partly in consequence of easing of 
European borders, allowing easier movement of working age adults seeking 
employment. The ethnic make-up of the white population in this area has changed, 
growing from 3.3% in 2001 to 7.2% in 2011. This is due to an influx of a largely Eastern 
European population e.g. Polish. The remainder of the population are of a black and 
ethnic minority population predominately of Indian sub-continent heritage. The district 
is the 67th out of 326 districts, most deprived districts in England, with 12.5% living in 
areas rated in the 10% most deprived. Life expectancy of local males is 77 years and 
81 years for females. Cancer incidence and mortality in this district is higher than other 
manufacturing towns in England 43.
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Patients aged over 18 years with a histological diagnosis of NMIBC were included in 
this analysis. They had a grading of grade 3 bladder cancer with one, or a combination 
of, the following stages: Ta; T1; or carcinoma in situ (CIS). Commencing BCG 
treatment within the 12 months prior to the commencement of this study and had 
withdrawn from treatment. Patients who had progression or recurrence of bladder 
cancer and were not receiving BCG treatment were excluded.
A sample of 234 sets of patient case notes (1st January 2004 to 31st December 2011), 
fitted the inclusion criteria, which were included in this study. This was considered 
representative of the population 44. The characteristics of the sample are described in 
table 2.
Ethical approval was obtained from local research ethics committee (12/YH/0481) and 
the university where study was conducted. The researchers were not involved in the 
administration of intravesical BCG treatment or in the management of any of the 
healthcare professionals (HCPs) within the units where treatment was given. 
3. Data Collection 
A data extraction tool was designed and pilot tested by the researcher. Only the 
researcher conducted the data extraction. The clinical data relating to BCG treatment 
received by patients gathered also illustrated the ‘natural history’ of BCG treatment 
and identified trends concerning symptomology e.g. timing of symptom occurrence 
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and decisions recorded for treatment withdrawal. The tool was tested on a sample 
selection of case notes (n=10) and adjustments made to refine the tool.
During the study, the NHS Trust moved towards being ‘paper-light’, hampering 
healthcare records collection of the data in three ways. Firstly, for those patients who 
still had paper notes, locating the notes and in many cases retrieving from storage 
took multiple requests and time delays. Secondly, paper notes already scanned into 
the electronic data management system posed different challenges. Such as delays 
caused by the time taken to scan documents and upload them and two the volume of 
screens of scanned documents per case note, as many as 500, which needed to be 
reviewed to extract relevant data. Thirdly, some prescription cards were held by each 
unit and not with the case notes and these needed to be examined separately. 
4. Data Analysis
Once extraction was completed, all data were transferred into IBM SPSS version 20 
for Windows. Data were then analysed using the Kaplan-Meier method. This allows 
estimation of withdrawal over time, even when patients remain the study  for different 
lengths of time 45. Cox regression modelling was used to interrogate withdrawal data, 
allowing treatment effects to be isolated from influences of other variables 45,46.
5. Results
There appears to be several significant factors or patterns that arise from the case-
note analysis, which indicates a withdrawal rate of 90% and that the majority withdraw, 
107 (46%), from treatment within the first year. The most commonly recorded side 
effects involved a treatment related pain dimension e.g. pain, cystitis, sore genitalia. 
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Urinary side effects such as frequency and urgency were also commonly reported. 
Age was also an important factor, as those who were 70 years or over were more likely 
to withdraw from treatment.
The findings are presented in five sections: study population and characteristics; 
patterns of withdrawal; factors influencing withdrawal; decisions for withdrawal; and 
Likelihood of withdrawal. The term ‘time to event’ for this study is defined as being the 
time taken to the event of interest namely withdrawal from BCG treatment. 
6.1. Study population and characteristics 
Most participants were aged over 70 years, 140 (61%), and the majority were male, 
188 (80%). Only 23 (10%) of the sample population completed the full three-year 
treatment regimen lower than the 16% identified in the South Western Oncology Group 
(SWOG) trial 9.
Table. 2.
6.2. Patterns of withdrawal
The time to event analysis looked at protocol deviation by charting each instillation 
and the timing between instillations. Thereby, looking for patterns or areas of 
variability. These variations can be seen in Figures 1-7, which illustrate a number of 
curves. The significance of the divergent patterns is addressed with the log rank test, 
this showed that there was correlation with age and that the chance of an event 
occurring e.g. having a side effect, rises with age. The data also shows that those who 
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experienced one or more side effects were more likely to withdraw from treatment 
early, 71 (53%) withdrawing within 35 days of starting treatment. 
Fig. 1 shows when each participant completed treatment. The largest withdrawal 
occurs prior to the one-year mark. From these data, 36 (15%), of patients extended 
treatment beyond the three-year treatment protocol. This may be due to delays in the 
instillations, which then offset other instillations, being given later than planned, or the 
possibility that the patient had been lost to follow up and then continued when found. 
Fig. 1.
Figure 2 shows that by concentrating the curve to 36 months, representing three years 
of treatment, it shows that patients are more likely to withdraw from treatment within 
the first 365 days (one year). On interrogation of those 107 (46%) of patients that 
withdrew by 12 months, one year), of treatment a greater proportion, 39 (36%), 
withdrew within the first 42 days (see Figure 3).
Fig. 2.
Fig. 3.
6.3. Factors influencing withdrawal
Fig. 4 shows comparison of time to withdrawal from treatment by age. Participants 
aged over 70 years have a lower time to event probability than those aged 69 years 
or younger. Log rank statistic 17.34 (p=0.001). Age in this population was a significant 
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factor in withdrawal from treatment. Likewise, those who experienced one or more side 
effect associated with BCG treatment (log rank statistic 7.27 (p=0.007)) were more 
likely to withdraw from treatment (See Figure 5).
Fig. 4. 
Fig. 5. 
As contact with a clinical nurse specialist (CNS) is one of the standards recommended 
in cancer standards 47 compliance with this requirement was extracted from the case 
notes. Figure. 6 shows if a record of a patient receiving CNS contact information 
whereas Figure 7 illustrates receiving information about the treatment from a CNS. 
From these data it appears that receipt of contact details of a CNS (log rank statistic 
4.46; p= 0.035) or receiving information about the procedure and side effects (log rank 




6.4. Decisions for withdrawal
The reasons recording decisions to withdraw from treatment were categorised into five 
broad areas: Side effects, patient/carer, hospital related, disease related, or other 
reasons. The largest single grouping was treatment associated side effects (see 
Figures 8-10). The time to event analysis revealed, what appeared to be a natural age 
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group split.  Participants were grouped 69 years or younger and those aged 70 years 
or over. When categorised by age, there was little difference in the reasons given for 
withdrawing from treatment. Documented side effects appeared to be a major 
contributor to the decision to withdraw with two thirds, 156 (67%) of participants, with 




Side effects experienced are shown in Figs. 11-13. The majority of reported local 
symptoms were urinary including frequency of urination (n=41, 39%), haematuria (n= 
33, 31%), cystitis (n= 29, 28%) etc.  Generalised pain which was not localised (n=22, 
31%) was reported as being the most common systemic side effect. Unknown 
reactions (where a reaction was recorded, but no details given) (n=18, 39%) and 
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6.5. Likelihood of withdrawal
In the Cox regression modelling that was undertaken, all variables were considered 
for inclusion were screened. Those which did not appear important individually or 
comprised categories with frequencies too low to analyse were excluded. The 
remaining variables were then analysed in combination to identify any emerging 
patterns. This method assumes that covariates are multiplicatively related to the 
hazard e.g. experiencing a side effects raises the likelihood of withdrawal 48. Variables 
included were those that: had a low p-value (<0.05) at ‘screening stage’ indicating the 
likelihood he variable occurring by chance was less than 5%; were clinically important 
(side effects recorded as reason for patient withdrawal); or those selected through 
automated selection routine which the proportionality of the hazards assumption was 
validated. The variables that appear significant are presented in Table 3.
Table 3
6. Discussion 
A major cause for early withdrawal was side effects, although age was associated with 
higher withdrawal rates. The reasons given for withdrawal from treatment were the 
same, or similar, in all age groups except for side effects. It was found that 31 (40%) 
of participants aged 69 years or younger side effects were cited as a reason for 
withdrawing from treatment, a higher proportion than the 44 (33%) of participants aged 
70 years or older. These results are in contrast to Heiner and Terris’s study, where the 
number of patients who experienced side effects aged 70 years or over were higher 
than in patients 69 years or younger respectively, 56% vs. 40% 49. Although reported 
as significant (p<0.00001), the study sample was small, 58 participants, with only 22 
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experiencing side effects suggesting it was underpowered. The number of participants 
who experienced side effects were greater 156 participants in this study; with 92 (59%) 
aged over 70 years experiencing at least one side effect. An alternate explanation 
could relate the strains and/or doses of BCG administered. In the absence of 
consistent practice regarding optimum strain or dose 30–32, this inconsistency may 
explain varying levels of withdrawal. Similarly, differences in number and severity of 
side effects experienced may strain or dose dependent. Within this analysis all patients 
received the same strain of BCG.
Some suggest that interstitial BCG treatment needs to be administered cautiously in 
patients 70 years or older and only after careful consideration due to poor reserves 
that these patients may have to cope with the treatment 50. This is predicated on the 
basis that side effects from BCG treatment would not be as well tolerated in elderly 
patients and may become problematic in terms of adherence. This pattern was seen 
in this study population. Whether this was a consequence of poor toleration or the 
treatment burden was in excess of physical reserves and/or co-morbidity was not 
assessed. 
The analysis supports the given view that side effects experienced affects attrition. 
Patients who are well prepared about what to expect, such as those involved in clinical 
trials, may be better prepared when encountering side effects; in effect they cope by 
normalising the abnormal. The results of this study suggest that those patients who 
are given more information, were more likely to withdraw. 
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A surprising feature of this study and should be treated cautiously, was contact with a 
CNS may not contribute to keeping patients on treatment for longer. The reasons for 
this finding are unknown but warrants further investigation, particularly, as in other 
cancer site specific studies CNS input seems to improve outcomes 51. However, this 
could be related to poor record keeping, in that those case records where details of 
the CNS were provided, patients were more likely to withdraw from treatment early, 
than those whose records showed they only received written information.
The time to event analysis of withdraw from treatment revealed a natural age group 
split with patients 69 years and under more likely to tolerate and continue to receive 
BCG for nine months longer than those aged 70 years and above. Further, 63% of the 
population aged above 70 years old in this study were more likely to withdraw reasons 
for attrition were similar. Not only was there a correlation between age and the chance 
of the event occurring, but the modelling highlighted that the percentage chance of the 
event occurring rises with age.
During data extraction three patient records documented the rationale for treatment 
cessation as ‘advanced age’. This does question whether an adequate assessment 
was completed prior to treatment. The higher number of participants aged 70 years or 
greater in the study probably reflects the local population, with increasing life 
expectancy and effects of exposure to dye, printing, iron, industrial painting, gas and 
tar industries during employment only presenting long after exposure 8. This 
generation may not have benefitted from the impact of health and safety legislation in 
the work place or recent anti-smoking campaigns 52. 
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There is clear evidence of side effects associated with BCG use 9,26,27. Reportedly 
between 20% and 80% of patients experience mild to severe local or systematic, side 
effects 53–55. The reported studies do not detail the effect that side effects have on the 
patient.
This study discovered that 67% of patients who experienced one or more side effect, 
such as cystitis or incontinence, were more likely to withdraw early. The analysis 
showed that 55% of participants withdrew within the first year. Of these, 39% withdrew 
within 42 days of treatment commencing, hence failing to complete the induction 
phase of the treatment (the initial six instillations). Data regarding subsequent 
treatment(s) if any or long terms outcomes was not extracted and therefore any 
assumptions about whether patients were being put at risk of recurrence through early 
withdrawal are unknown. That said poor selection for BCG may have delayed 
alternative interventions.   
Nearly half of the of participants (45%) reported at least one local side effect e.g. 
urinary frequency; with 30% reporting at least one systemic side effect; and 20% 
reporting at least one other side effect or treatment related complication e.g. difficulty 
in catheterisation. The most common local side effect reported was cystitis and 
according to Lamm et al. experienced in around 80% receiving BCG 53. In contrast, in 
this study, cystitis was recorded in only 28% of cases (Fig. 11). The most commonly 
recorded local side effect in was urinary frequency in 39% of cases. A possible reason 
for differences in symptom incidence may relate to how side effects were reported 
and/or recorded in case notes. Cystitis involves both frequency and pain, or a burning 
sensation, when urinating 56. As the instillation of BCG is largely a nurse led service, 
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in that the CNS counsels the patient, instils the BCG, records in the case notes and 
discharges the patient from the unit. They remain the main contact for the patient when 
they go home, therefore, this impacts onto any findings. The CNS may have recorded 
these side effects separately, or one in preference to both, or interpreted the 
symptoms and given a different descriptor thereby skewing the actual number of 
participants who did have the side effect of cystitis.
It is unclear in the literature when side effects occur. Some authors indicate that side 
effects can occur during the induction phase of the treatment, however they do not 
suggest that there is a cumulative effect from the BCG instillations when the symptoms 
appear during maintenance 49,57–59. In this study there were 53% reports of side effects 
experienced within 35 days of starting treatment indeed for some these started within 
the first week of treatment commencing. 
A limitation of all studies interrogating clinically available data, is the quality of the 
original record keeping and accuracy of data extraction. As this study used paper-
based notes (patient records and prescription charts) this may have introduced greater 
levels of inaccuracy as clinician preference and style may influence what is recorded. 
Unlike electronic records which force data entry arguably increasing reliability 60. 
Although some suggest the problem of data accuracy has more to do with why it is 
collected namely research versus clinical purposes. The introduction of electronic 
health records may have increased the tendency for bad data recording rather than 
greater accuracy 61.
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From this retrospective time interval analysis of clinical data withdrawal rates from 
BCG treatment were higher than those published in the literature. The patterns that 
emerged associated with age and experience of side effects appeared to significantly 
affect the decision making regarding early withdrawal from treatment. The majority of 
attrition appears to occur within the first year of treatment, and indeed a sizable group 
prior to completing induction. Possibly the most surprising finding was that clinical 
nurse contact and information provision seemed to exacerbate early withdrawal. This 
may be an anomaly associated with a real-world nurse led service design. What is 
clear is that further research is required to fully understand these results, but they 
contribute real world insight into the experience of a ‘gold standard’ treatment. 
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Fig. 1: Early withdrawal or course completion overall view
Fig. 2: Early withdrawal or completed 36 months (three years) of treatment
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Fig. 3: Early withdrawal or completed 12 months (one year) of treatment
Fig. 4: Treatment withdrawal by age group
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Fig. 5: Early withdrawal through side effects
Fig. 6: CNS contact details given to a patient
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Fig. 7: Written information given to a patient
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Fig. 9: Comparison of withdrawal reasons by age
TOTAL SIDE EFFECTS HOSPITAL PATIENT / CARER DISEASE OTHER
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Table 1: Studies showing BCG dose, strain and treatment regime
Study Dose / Strain Induction Regime Maintenance Regime Percutaneous BCG
Morales et al. (1976) 120mg / Armand Frappier Weekly for 6 weeks No Yes
Herr et al. (1983) 120mg / Armand Frappier Weekly for 6 weeks No Yes
Badalament et al. (1987) 120mg / Armand Frappier Weekly for 6 weeks Monthly for 2 years No
Hudson et al. (1987) 120mg / Pasteur No 1 instillation every 3 months for 2 years No
Agrawal et al. (2007) 40,80,120mg / Modified Danish 1331 Weekly for 6 weeks Monthly for 1 year No
Ali-el-dein et al. (1999) 150mg / Strain not given Weekly for 6 weeks Monthly for 10 months No
Andius & Holmang (2004) Dose not stated / Modified Danish 1331 & TICE Weekly for 6 weeks Monthly for 2 years No
Orihuela et al. (1987) 120mg / Pasteur Weekly for 6 weeks No Yes
Lamm et al. (1995) 50 mg / TICE Weekly for 6 weeks Monthly for 1 year No
Bohle et al. (1996) 150mg / Connaught Weekly for 6 weeks No No
Krege et al. (1996) 120mg / Connaught Weekly for 6 weeks Monthly for 4 months No
Taniguchi et al. (1999) 80mg / Tokyo 172 Weekly for 6 weeks No No
Witjes et al. (1996) 5x108 / TICE & RIVM Weekly for 6 weeks No No
Witjes et al. (1998) 40mg of Mitomycin C then BCG Weekly for 6 weeks No No
Lamm et al. (2000) 81mg / Connaught Weekly for 6 weeks
Weekly for 3 weeks at 
months 3, 6, 12, 18, 24, 
30 and 36 
Yes
Saint et al. (2001) 81mg / Connaught Weekly for 6 weeks
Weekly for 3 weeks at 
months 3, 6, 12, 18, 24, 
30 and 36
No
van der Meijden et al. (2001) 5x108 / TICE Weekly for 6 weeks
Weekly for 3 weeks at 
months 3, 6, 12, 18, 24, 
30 and 36
No
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Fonseca et al. (2002) 40mg / Moreau-Rio de Janeiro 
6 instillations – not 
clear over what time 
period
6 instillations each 15 
days No
van der Meijden et al. (2003) 5x108 / TICE Weekly for 6 weeks
Weekly for 3 weeks at 
months 3, 6, 12, 18, 24, 
30 and 36
No
De Reijke et al. (2005) 81mg / Connaught Weekly for 6 weeks
Weekly for 3 weeks at 
months 3, 6, 12, 18, 24, 
30 and 36
No
Gunlusoy et al. (2005) 120mg / Pasteur Weekly for 6 weeks No No
Decobert et al. (2008) 120mg / Pacis Shire Weekly for 6 weeks
Weekly for 3 weeks at 
months 3, 6, 12, 18, 24, 
30 and 36
No
Jarvinen et al. (2009) 75mg / Pasteur Weekly for 5 weeks Monthly for 2 years No
Duchek et al. (2010) Dose not stated / TICE Weekly for 6 weeks
Weekly for 3 weeks at 
months 3, 6, 12, 18, 24, 
30 and 36
No
Hinotsu et al. (2010) 81mg / Connaught Weekly for 6 weeks Weekly for 3 weeks at months 3, 6, 12 and 18 No
Sylvester et al. (2010) 5x108 / TICE Weekly for 6 weeks
Weekly for 3 weeks at 
months 3, 6, 12, 18, 24, 
30 and 36
No
Oddens et al. (2014) 5x108 / TICE Weekly for 6 weeks
Weekly for 3 weeks at 
months 3, 6, 12, 18, 24, 
30 and 36; or
No
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Weekly for 3 weeks at 
months 3, 6 and 12 
Rentsch et al. (2014) 6.6–19.2 108 CFU / Connaught 2–8 108 CFU / Tice Weekly for 6 weeks No No
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Table 2: The age distribution and gender of the population
Table 3: Cox regression model parameters










<59 0.007 0.427 0.231 0.789
60-69 0.018 0.558 0.345 0.903
70-79 0.241 0.765 0.490 1.197
Patients withdrawn due to:
No side effects or side effects 
(reference)
Side effects or side effects <0.001 5.443 3.481 8.510
No patient or carer decisions (reference)
Patient or carer decisions 0.002 2.379 1.368 4.134
No hospital events (reference)
Hospital events <0.001 2.898 1.736 4.837
No miscellaneous reasons (reference)
Miscellaneous reasons <0.001 7.057 4.308 11.561
Patients who received:
No information (reference)
Information <0.001 1.857 1.322 2.610
Patients who experienced:
No local side effects (reference)
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